

**Drug Utilization Review Board**  
(DUR Board)  
**Meeting – December 10, 2008 @ 6:00 p.m.**

Oklahoma Health Care Authority  
4545 N. Lincoln Suite 124  
Oklahoma City, Oklahoma 73105  
**Oklahoma Health Care Authority Board Room**

---

**AGENDA**

Discussion and Action on the Following Items:

Items to be presented by Dr. McNeill, Chairman:

1. **Call To Order**
  - A. Roll Call – Dr. Graham

Items to be presented by Dr. McNeill, Chairman:

2. **Public Comment Forum**
  - A. Acknowledgment of Speakers and Agenda Item

Items to be presented by Dr. McNeill, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A.**
  - A. November 12, 2008 DUR Minutes – Vote
  - B. Provider Correspondence

Items to be presented by Dr. Keast, Dr. McNeill, Chairman:

4. **Update on DUR/MCAU Program – See Appendix B.**
  - A. Retrospective Drug Utilization Review for September 2008
  - B. Retrospective Drug Utilization Review Responses for July 2008
  - C. Medication Coverage Activity Audit for November 2008
  - D. Help Desk Activity Audit for November 2008

Items to be presented by Dr. Chonlahan, Dr. McNeill, Chairman:

5. **Action Item – Annual Review of Bladder Control PBPA Category and 30 Day Notice to Prior Authorize Toviaz<sup>®</sup> – See Appendix C.**
  - A. Current PA Criteria
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Le, Dr. McNeill, Chairman:

6. **Action Item – Annual Review of Statins/Zetia<sup>®</sup> PBPA Category and 30 Day Notice to Prior Authorize Simcor<sup>®</sup> – See Appendix D.**
  - A. Current PA Criteria
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Patel, Dr. McNeill, Chairman

7. **Action Item – Annual Review of Symlin<sup>®</sup> and Byetta<sup>®</sup> – See Appendix E.**
  - A. Current PA Criteria
  - B. Utilization Review
  - B. COP Recommendations

Items to be presented by Dr. Moore, Dr. McNeill, Chairman

8. **Utilization Review of Oral Antifungals and 30 Day Notice to Apply Age Restriction to Lamisil<sup>®</sup> Granules – See Appendix F.**
  - A. Product Summary
  - B. Utilization Review
  - C. COP Recommendations

Items to be presented by Dr. Keast, Dr. McNeill, Chairman

9. **Utilization Report for First Quarter Fiscal Year 2009 and Fiscal Year 2008 Annual Review – See Appendix G.**
  - A. First Quarter FY 2009 Top 25 Sub-Therapeutic Classes by Reimbursement
  - B. First Quarter FY 2009 Top Therapeutic Classes with Top Five Products by Reimbursement
  - C. FY 2008 Utilization Summary
  - D. FY 2008 Comparison of Top 100 Medications by Reimbursement
  - E. FY 2008 Top 50 Medications by Number of Claims
  - F. FY 2008 Comparison by Therapeutic Category

Items to be presented by Dr. Le, Dr. McNeill, Chairman

10. **Retrospective Drug Utilization Review Program Demonstration**

Items to be presented by Dr. Graham, Dr. McNeill, Chairman

11. **FDA and DEA Updates – See Appendix H.**

12. **Future Business**
  - A. Lock-In Report
  - B. Annual Review of Ocular Antibiotics
  - C. Annual Review of Brovana<sup>®</sup>
  - D. New Product Reviews

13. **Adjournment**